drugset
drugset / Trial / NCT03978884

Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes

NCT03978884 ↗

Phase 4 Withdrawn The University of The West Indies Caribbean College of Family Physicians · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To study antihypertensive efficacy of 12 weeks of Losartan based therapy Resilo (Losartan) and Resilo-H (Losartan+ Hydrochlorothiazide) in uncontrolled hypertensive and diabetic hypertensive patients.

Timeline

Start
2019-06-01
Primary completion
2020-05-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral
Subject Losartan Other / unclassified 50 mg Oral
Subject Losartan Other / unclassified 100 mg Oral

Indications

diabetes mellitus hypertensive disorder